NKTR Nektar Therapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:07
Jul 15
Jul 15
Author discloses existing long position in NKTR, expressing desire for larger exposure within the broader XBI bullish thesis of macro tailwinds and record sector M&A.
MED
20:04
Jul 10
Jul 10
Long NKTR as author holds existing position citing undervaluation and multiple near-term catalysts including Phase 3 initiation, potential Lilly settlement, collaboration, or M&A.
MED
20:09
Jul 06
Jul 06
Buy NKTR as author increased position citing potential undisclosed corporate event; long-tenured employees marking themselves open to work on LinkedIn, combined with prior tea leaves, suggests possible M&A or strategic announcement, with limited downside if nothing materializes.
MED
18:06
Jul 06
Jul 06
Buy NKTR ahead of a potential business development catalyst; author increased position citing CEO's June 4 collaboration commentary, unusual management silence since May, LinkedIn staff marking themselves open-to-work, and stock retracing to attractive levels post-offering — not expensive even if no deal materializes.
MED
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
20:01
Jul 02
Jul 02
The tweet expresses excitement about these biotech tickers with no explicit position or directional call, so they are indexed as watch.
LOW
17:44
Jul 02
Jul 02
Author highlights NKTR's stalled Phase 3 trial, sparse updates, and management's vague collaboration comments as concerning signals for the stock.
LOW
09:26
Jul 01
Jul 01
Maintain existing long position in NKTR on a fair-value recovery thesis; author views current price as significantly below intrinsic value but acknowledges it is at an earlier/riskier stage than ABVX.
MED
10:24
Jun 30
Jun 30
Author holds a full position in NKTR, arguing it is well-capitalized and cheap at ~$1B EV while XBI is up 20%; bear thesis of "opportunity cost/time" is self-defeating as upcoming settlement, trial, and partnership/sale catalysts approach.
MED
17:40
Jun 28
Jun 28
Author increased their ABVX position as a concentrated conviction bet on Obe commercialization at ~$8B market cap, while closing COGT and BCRX for decent returns, and notes XBI outperformance as a positive sector signal.
LOW
16:52
Jun 24
Jun 24
The tweet humorously recounts a mistaken short report rumor about ABVX causing NKTR to sell off, but no trade position is stated.
LOW
00:00
Jun 24
Jun 24
Buy NKTR as the APGE/$ABBV deal (3-4x peak sales) establishes a valuation framework for AtD assets; Rezpeg's differentiated 2L MOA (non-Th2, post-Dupi/JAK niche) and durability profile support a risk-adjusted EV of $2-4B vs ~$1B current EV, implying 2-4x upside on AtD alone before AA/other indication optionality.
HIGH
00:32
Jun 23
Jun 23
The tweet reports market cap increases for KYMR and NKTR without expressing a personal position or forward-looking trade view.
LOW
13:29
Jun 22
Jun 22
Buy NKTR on the thesis that its exclusively post-biologic Phase 3 in atopic dermatitis — the first of its kind — positions it to dominate the second-line market upon a successful readout, a differentiated clinical catalyst not yet priced in.
MED
11:53
Jun 22
Jun 22
The author declares OX40 target dead and questions SNY's Amlitelimab continuation, but provides no personal position or forward trade call.
LOW
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
22:03
Jun 20
Jun 20
The author argues that no drugs targeting the mentioned pathways are on the market and will not be before NKTR, but this is a factual rebuttal rather than a trade idea.
LOW
21:21
Jun 20
Jun 20
The author asks about the mechanism of action for patients failing IL4/13 therapy, referencing NKTR without taking a directional position.
LOW
11:43
Jun 20
Jun 20
Author defends NKTR's trial design and commercial positioning, countering bearish concerns about patient demographics. No directional view.
LOW
20:12
Jun 19
Jun 19
Buy NKTR ahead of Ph3 with ~$1B EV vs risk-adjusted $2-4B for Rezpeg alone; APGE's $11B AbbVie takeout at 3-4x peak sales revalidates AtD as M&A battleground, Rezpeg's novel Treg/non-Th2 MOA differentiates it as a 2L asset immune to class-failure dynamics, and multiple large-cap buyers (INCY, SNY, LLY, ABBV) are credible acquirers.
HIGH
15:42
Jun 19
Jun 19
Buy NKTR as the best-value play in atopic dermatitis; a ~$10B EV M&A deal for a 4th-to-market IL4/13 inhibitor (APGE) implies significant upside re-rating for NKTR at ~$1B EV, which has a unique MoA, Q3M dosing, and Phase 3 starting next month.
HIGH
15:02
Jun 19
Jun 19
Buy NKTR ahead of Monday open; author argues novel mechanisms in the atopic dermatitis space are undervalued relative to $APGE, implying a 50%+ mispricing that could correct sharply.
MED
14:34
Jun 19
Jun 19
Author reviews merger documents and identifies read-through targets for potential takeovers, but does not state personal positions or forward calls.
00:16
Jun 15
Jun 15
Named as potential public AtD takeout candidate alongside KYMR/AGPE/CRVS if BP shifts M&A focus from privates to public companies.
MED
20:41
Jun 12
Jun 12
Author notes NKTR is up 600% since a controversial post, but does not state a current position or forward call.
LOW
18:11
Jun 12
Jun 12
Buy NKTR as author increased position; M&A strategic interest and litigation can run concurrently, creating a win-win catalyst path — strategic buyer interest removes need for a large standalone settlement, and Rezpeg has a credible market position at current cheap valuation.
MED
15:38
Jun 08
Jun 08
Buy NKTR as a likely M&A target for Incyte, which has confirmed interest in I&I bolt-on acquisitions; NKTR offers plug-and-play commercial fit with Incyte's existing Oplezura salesforce, a differentiated biologic MoA, Phase 3-ready Rezpeg, and a board member who is Incyte's co-founder — reducing deal friction.
MED
15:21
Jun 08
Jun 08
Author suggests NKTR could move higher in their opinion but uses hedged language without stating a position or explicit forward call.
LOW
21:57
Jun 06
Jun 06
Author holds NKTR as second-largest position, added aggressively in the 90s; thesis is that Rezpeg's clinical efficacy is broadly accepted by physicians, valuation has compressed to cheap levels, and historical pattern of sharp reversals supports a mean-reversion long.
MED
About NKTR Analyst Coverage
Buzzberg tracks NKTR (Nektar Therapeutics) across 2 sources. 54 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (64%). 84 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: seedy19tron, A May MD.